Grigg Ingham will acquire Vira Therapeutics
-
Last Update: 2021-02-26
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Ingham has chosen to buy a stake in Vira Therapeutics, a lysovirus company.
Vira Therapeutics will operate in Innsbruck, Austria, as a unique unit of the Bringer Discovery Research Organization, "maintaining its innovative biotechnology heritage and maintaining close ties with innsbruck Medical University and the regional scientific community." The German drugmaker said.
the team specializes in the development of lysovirus therapies, and its main candidate is VSV-GP (blistered oral inflammatory virus (VSV) with modified glycoprotein (GP), which is being studied separately and used in combination with other therapies.
press conference, VSV-GP showed promising results in preclinical models, especially in combination with key immunomodulation principles being developed by Bronger.
's acquisition of Vira Therapeutics on an exciting lysozy virus platform is the result of two years of trust and close cooperation," said Dr. Heinz Schwer, CHIEF Executive Officer of Vira Therapeutics. " (China Medicine 123 Network)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
